Regenerative Medical Technology (RMTG) Total Non-Current Liabilities (2021 - 2026)
Regenerative Medical Technology (RMTG) posted quarterly Total Non-Current Liabilities of $39.3 million for Q1 2026, up 22.49% year-over-year from $32.1 million in Q1 2025, and up 6.74% quarter-over-quarter from $36.8 million in Q4 2025.
Regenerative Medical Technology (RMTG) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends
Regenerative Medical Technology's Total Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $39.3 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 22.49% year-over-year to $39.3 million; the TTM figure through Mar 2026 stood at $39.3 million (up 22.49% YoY), while the FY2025 annual figure was $36.8 million, up 18.14% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $39.3 million, up from $36.8 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $39.3 million in Q1 2026, with the low at $17.1 million in Q1 2022.
- The 5-year median for Total Non-Current Liabilities is $26.8 million (2024), against an average of $27.2 million.
- The sharpest annual moves came in 2023 and 2025: Total Non-Current Liabilities climbed 29.29% in 2023, then increased 15.45% in 2025.
- Regenerative Medical Technology's Total Non-Current Liabilities stood at $20.1 million in 2022, then grew by 23.02% to $24.7 million in 2023, then grew by 26.35% to $31.2 million in 2024, then rose by 18.14% to $36.8 million in 2025, then increased by 6.74% to $39.3 million in 2026.
- Business Quant data shows RMTG's Total Non-Current Liabilities at $39.3 million in Q1 2026, $36.8 million in Q4 2025, and $34.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Regenerative Medical Technology | 1.58 Mn | 515,228.12 | 1.77 Mn | 39.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 39.31 Mn |
| Dec 31, 2025 | 36.83 Mn |
| Sep 30, 2025 | 34.57 Mn |
| Jun 30, 2025 | 33.50 Mn |
| Mar 31, 2025 | 32.09 Mn |
| Dec 31, 2024 | 31.17 Mn |
| Sep 30, 2024 | 29.94 Mn |
| Jun 30, 2024 | 28.88 Mn |
| Mar 31, 2024 | 26.83 Mn |
| Dec 31, 2023 | 24.67 Mn |
| Sep 30, 2023 | 24.85 Mn |
| Jun 30, 2023 | 23.22 Mn |
| Mar 31, 2023 | 21.71 Mn |
| Dec 31, 2022 | 20.06 Mn |
| Sep 30, 2022 | 19.22 Mn |
| Jun 30, 2022 | 18.01 Mn |
| Mar 31, 2022 | 17.12 Mn |
| Dec 31, 2021 | 16.04 Mn |